F
František Toušek
Publications - 40
Citations - 1843
František Toušek is an academic researcher. The author has contributed to research in topics: Myocardial infarction & Percutaneous coronary intervention. The author has an hindex of 8, co-authored 39 publications receiving 1630 citations.
Papers
More filters
Journal ArticleDOI
Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events
Deepak L. Bhatt,Gregg W. Stone,Kenneth W. Mahaffey,C. Michael Gibson,P. Gabriel Steg,Christian W. Hamm,Matthew J. Price,Sergio Leonardi,Dianne Gallup,Ezio Bramucci,Peter W. Radke,Petr Widimský,František Toušek,Jeffrey Tauth,Douglas Spriggs,Brent T. McLaurin,Dominick J. Angiolillo,Philippe Généreux,Tiepu Liu,Jayne Prats,Meredith Todd,Simona Skerjanec,Harvey D. White,Robert A. Harrington +23 more
TL;DR: Cangrelor significantly reduced the rate of ischemic events, including stent thrombosis, during PCI, with no significant increase in severe bleeding.
Journal ArticleDOI
Intravenous Platelet Blockade with Cangrelor during PCI
Deepak L. Bhatt,A. Michael Lincoff,C. Michael Gibson,Gregg W. Stone,Steven McNulty,Gilles Montalescot,Neal S. Kleiman,Shaun G. Goodman,Harvey D. White,Kenneth W. Mahaffey,Charles V. Pollack,Steven V. Manoukian,Petr Widimsky,Derek P. Chew,Fernando A. Cura,Ivan H Manukov,František Toušek,M. Zubair Jafar,Jaspal Arneja,Simona Skerjanec,Robert A. Harrington +20 more
TL;DR: The use of periprocedural cangrelor during PCI was not superior to placebo in reducing the primary end point, and the prespecified secondary end points of stent thrombosis and death were lower in the cang Relor group, with no significant increase in the rate of transfusion.
Journal ArticleDOI
Prasugrel Versus Ticagrelor in Patients With Acute Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention: Multicenter Randomized PRAGUE-18 Study.
Zuzana Motovska,Ota Hlinomaz,Roman Miklík,Milan Hromádka,Ivo Varvarovsky,Jaroslav Dušek,Jiri Knot,Jiri Jarkovsky,Petr Kala,Richard Rokyta,František Toušek,Petra Kramarikova,Bohumil Majtan,Stanislav Šimek,Marian Branny,Jan Mrózek,Pavel Červinka,Jiri Ostransky,Petr Widimsky +18 more
TL;DR: No randomized head-to-head comparison of the efficacy and safety of ticagrelor and prasugrel has been published in the 7 years since the higher efficacy of these newer P2Y12 inhibitors w...
Journal ArticleDOI
1-Year Outcomes of Patients Undergoing Primary Angioplasty for Myocardial Infarction Treated With Prasugrel Versus Ticagrelor
Zuzana Motovska,Ota Hlinomaz,Petr Kala,Milan Hromádka,Jiri Knot,Ivo Varvarovsky,Jaroslav Dušek,Jiri Jarkovsky,Roman Miklík,Richard Rokyta,František Toušek,Petra Kramarikova,Michal Svoboda,Bohumil Majtan,Stanislav Šimek,Marian Branny,Jan Mrózek,Pavel Červinka,Jiri Ostransky,Petr Widimsky +19 more
TL;DR: Prasugrel and ticagrelor are similarly effective during the first year after MI and patients who were economically motivated to switch to clopidogrel had a lower risk of major cardiovascular events; however, they also had lower ischemic risk.
Journal ArticleDOI
Catheter ablation for paroxysmal atrial fibrillation: a randomized comparison between multielectrode catheter and point-by-point ablation.
Alan Bulava,Jiří Haniš,David Sitek,Ondřej Ošmera,Dan Karpianus,Michal Šnorek,Kateřina Rehoušková,František Toušek,Ladislav Pešl +8 more
TL;DR: Catheter ablation for paroxysmal atrial fibrillation is widely used for patients with drug‐refractoryParoxysms of arrhythmia and novel technologies have been introduced to the market that aim to simplify and shorten the procedure.